Nuvation Bio (NUVB) Current Leases (2021 - 2026)
Nuvation Bio (NUVB) posted quarterly Current Leases of $1.8 million for Q1 2026, down 2.7% year-over-year from $1.9 million in Q1 2025, and down 2.23% quarter-over-quarter from $1.9 million in Q4 2025.
Nuvation Bio (NUVB) Current Leases (2021 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Current Leases for 6 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases fell 2.7% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (down 2.7% YoY), while the FY2025 annual figure was $1.9 million, up 13.05% from the prior year.
- Current Leases declined to $1.8 million in Q1 2026 per NUVB's latest filing, from $1.9 million in the prior quarter.
- Across five years, Current Leases topped out at $2.1 million in Q2 2024 and bottomed at $697000.0 in Q1 2022.
- Historically, Current Leases has averaged $1.6 million across 5 years, with a median of $1.8 million in 2025.
- Annual changes were most pronounced in 2023 — Current Leases soared 78.48% — and 2024, when it fell 15.67%.
- Nuvation Bio's Current Leases stood at $1.2 million in 2022, then soared by 63.52% to $2.0 million in 2023, then retreated by 15.67% to $1.7 million in 2024, then advanced by 13.05% to $1.9 million in 2025, then decreased by 2.23% to $1.8 million in 2026.
- Business Quant data shows NUVB's Current Leases at $1.8 million in Q1 2026, $1.9 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 1.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.72 Mn |
| Mar 31, 2026 | 1.84 Mn |
| Dec 31, 2025 | 1.88 Mn |
| Sep 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Mar 31, 2025 | 1.89 Mn |
| Dec 31, 2024 | 1.66 Mn |
| Sep 30, 2024 | 1.78 Mn |
| Jun 30, 2024 | 2.08 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Dec 31, 2023 | 1.97 Mn |
| Sep 30, 2023 | 1.92 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | 1.24 Mn |
| Dec 31, 2022 | 1.21 Mn |
| Sep 30, 2022 | 1.10 Mn |
| Jun 30, 2022 | 941,000.00 |
| Mar 31, 2022 | 697,000.00 |
| Dec 31, 2021 | 863,000.00 |